AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00603083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
Trial: NCT00861796
Drug: CYR-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental arm
Trial: NCT00861796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00902941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily orally for 120 days
Trial: NCT00692458
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo; oral, once daily for approximately 60 months
Trial: NCT01985646
Drug: oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral probiotic
Trial: NCT02907437
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline as an add-on drug (200 mg/day)
Trial: NCT02907437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (200 mg/day)
Trial: NCT00827736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)
Trial: NCT00890890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
Trial: NCT02399397
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
Trial: NCT02460055
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
Trial: NCT02096614
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
Trial: NCT01014221
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
Trial: NCT00104767
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05642546
Drug: NM8074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
Trial: NCT05642546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Placebo
Trial: NCT01127906
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo suspension (matched to PF-04531083 suspension)
Trial: NCT01127906
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo tablet (matched to Oxycodone)
Trial: NCT02994784
Drug: Propylene Glycol-Free Melphalan Hydrochloride
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Propylene Glycol-Free Melphalan Hydrochloride
Trial: NCT00932971
Drug: PEG-IFN alfa-2a, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
Trial: NCT00371059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mgs BD
Trial: NCT00953914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
Trial: NCT00439166
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule, 100 mg, b.i.d., daily for 1 year
Trial: NCT00439166
Drug: Placebo matched to doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
Trial: NCT03988010
Drug: Placebo (for amantadine sulphate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 cc 0.9% sodium chloride
Trial: NCT03354637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution
Trial: NCT04340765
Drug: 18F-fluorocholine
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual phase 18F-fluorocholine PET/CT
Trial: NCT03072381
Drug: Corticosteroid Control - Group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
Trial: NCT01622348
Drug: IMO-3100 at 0.16 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
Trial: NCT03865953
Drug: LAT8881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAT8881 oral capsule
Trial: NCT03865953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT01622348
Drug: Saline for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
Trial: NCT01622348
Drug: IMO-3100 at 0.32 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
Trial: NCT02484560
Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00131963
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00131963
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01047475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6# TID with meal
Trial: NCT02772718
Drug: XOMA 358 single dose level A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 single dose level A administered by intravenous infusion
Trial: NCT02772718
Drug: XOMA 358 single dose level C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 single dose level C administered by an intravenous infusion
Trial: NCT00483028
Drug: donezepil (Aricept)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04071119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants administer the placebo (40 IU) twice a day for 5 - 7 days
Trial: NCT01731587
Drug: Cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
Trial: NCT04409522
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
Trial: NCT04129047
Drug: A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a multiple shade universal composite that needs prior shade selection procedure
Trial: NCT02556905
Drug: REVLIMID®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
Trial: NCT01044342
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule; single oral dose
Trial: NCT01044342
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, single oral dose
Trial: NCT01044342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, single oral dose
Trial: NCT00822003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control tablet
Trial: NCT02312206
Drug: NEOD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
Trial: NCT04065282
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 bid po D1\~14 Q3W, 3 cycles perioperation
Trial: NCT01777594
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Trial: NCT01910883
Drug: Placebo i.v. solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01512745
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Trial: NCT01975298
Drug: Avonex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon β1A 30 μg/0.5mL administered Intra Muscular
Trial: NCT01070823
Drug: Tysabri® (natalizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
Trial: NCT01434745
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
Trial: NCT00672958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching capsules.
Trial: NCT00380965
Drug: Cesamet™ (nabilone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02707523
Drug: Azithromycin 10 mg
RxNorm normalized name: azithromycin 10 MG/ML
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02707523
Drug: Azithromycin 20mg
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02707523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03514407
Drug: INCB059872
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
Trial: NCT04453501
Drug: favorable outcome
RxNorm normalized name: favor tutti frutti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
Trial: NCT00755417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Trial: NCT02669303
Drug: Methylprednisolone group
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
Trial: NCT03154840
Drug: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigate the Relative Bioavailability among Different Eutropin Formulations
Trial: NCT00813722
Drug: atenolol (beta blocker) and hydrochlorothiazide (diuretic)
RxNorm normalized name: amiloride / atenolol / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tid and 12,5 mg tid
Trial: NCT00406419
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablet was administered orally at a dose 7.5-25 mg
Trial: NCT00406419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to ocrelizumab was administered via IV infusion
Trial: NCT01206699
Drug: corticoid (altim® 1.5 ml)
RxNorm normalized name: Corticool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
Trial: NCT01206699
Drug: physiological solution (1.5 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
Trial: NCT00308737
Drug: Technosphere® Insulin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation, 15U/30U
Trial: NCT00308737
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive antidiabetes treatment at the discretion of their physicians
Trial: NCT01913639
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04261179
Drug: Nanocoll
RxNorm normalized name: rhenium sulfide, nanocolloidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg microgram(s), timepoint: 30-60 minutes
Trial: NCT03959852
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg/kg of Fentanyl IV administered over at least 1 minute
Trial: NCT00164710
Drug: lumefantrine-artemether
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00770588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match Gefitinib
Trial: NCT00080990
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00080990
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00630058
Drug: MP-424(H), PEG-IFN-a-2b, RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Trial: NCT00728299
Drug: PomWonderful Juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 oz per day each day for 78 weeks
Trial: NCT00728299
Drug: Placebo juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 oz per day for 78 weeks
Trial: NCT00630058
Drug: MP-424 (L), PEG-IFN-a-2b, RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Trial: NCT00361075
Drug: transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01448954
Drug: ADC3680B oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 28 days
Trial: NCT01448954
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 28 days
Trial: NCT01834586
Drug: Anesthetic Topical Adhesive Synera
RxNorm normalized name: Synera Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week
Trial: NCT00672282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00134771
Drug: Nutrient enriched infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01390441
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
Trial: NCT01079143
Drug: Certican®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
Trial: NCT03494465
Drug: MEDICAL GLAUCOMA TREATMENT
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
Trial: NCT00272350
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00272350
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01079143
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
Trial: NCT05240274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 500mg OD for 3 months to start within 10 days post-renal transplant
Trial: NCT03443414
Drug: RPL554 suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dual PDE3/PDE 4 inhibitor
Trial: NCT03443414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT03497715
Drug: Ibuprofen Sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test 2
Trial: NCT03497715
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test 3
Trial: NCT03497715
Drug: Ibuprofen (Nurofen)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference 1
Trial: NCT03497715
Drug: Ibuprofen (Wockhardt)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference 2
Trial: NCT00884897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given as 20 IU BID
Trial: NCT01602510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01151215
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, bd
Trial: NCT01151215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral
Trial: NCT02401971
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Ivgtt
Trial: NCT02078492
Drug: 10 mg of Ketorolac
RxNorm normalized name: ketorolac 10 MG
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 10 mg of Ketorolac for pain control.
Trial: NCT02078492
Drug: 15 mg of Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 15mg of Ketorolac for pain control.
Trial: NCT02078492
Drug: 30 mg of Ketorolac
RxNorm normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 30mg of Ketorolac for pain control.
Trial: NCT00288223
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
Trial: NCT04362137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-image placebo
Trial: NCT01779453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 8 weeks